logo
Angel Oak Financial Strategies Income Term Trust Announces Certified Results from 2025 Annual Meeting of Shareholders

Angel Oak Financial Strategies Income Term Trust Announces Certified Results from 2025 Annual Meeting of Shareholders

Business Wire10-07-2025
ATLANTA--(BUSINESS WIRE)--Angel Oak Financial Strategies Income Term Trust (NYSE: FINS) (the "Fund") has announced the final certified voting results from the 2025 Annual Meeting of Shareholders held on June 26, 2025 (the 'Annual Meeting').
Proposal 1: Approval of New Investment Advisory Agreement
For
Against
Abstain
11,417,091
4,840,580
126,687
Expand
Proposal 2: Election of Trustees
Nominees
For
Against
Abstain
Keith M. Schappert (Incumbent)
9,045,421
1,056,841
132,174
Andrea N. Mullins (Incumbent)
1,030,778
132,652
Trevor Montano (Challenger)
7,655,890
73,367
6,881
Expand
Proposal 3: Ratification of Auditor
A total of 25,062,638.4 shares were entitled to vote as of the record date of April 16, 2025, out of which 17,970,576 were present at the Annual Meeting. Despite the strong support, neither the new investment advisory agreement nor the Trustees received enough votes to pass the required vote thresholds. In the coming months, FINS will communicate with shareholders regarding a special shareholder meeting after accounting for the results from the Annual Meeting. In addition, FINS will continue engaging with shareholders as it evaluates several shareholder-friendly enhancements for the Fund.
FINS appreciates its shareholders' continued support of the Fund and of Angel Oak Capital Advisors, LLC, the Fund's adviser ('Angel Oak'). Angel Oak has successfully managed FINS since its inception in 2019. FINS has focused on enhancing long-term shareholder value with proactive actions aimed at improving liquidity, efficiency, and performance. Shareholders most recently demonstrated their support of FINS' performance through significant oversubscription in its recent rights offering in May 2025.
The final voting results have been certified by First Coast Results, Inc., the independent Inspector of Election, and will be included in FINS' next semi-annual or annual report to shareholders, as applicable.
ABOUT FINS
Led by Angel Oak's experienced financial services team, FINS invests predominantly in U.S. financial sector debt as well as selective opportunities across financial sector preferred and common equity. Under normal circumstances, at least 50% of FINS' portfolio is publicly rated investment grade or, if unrated, judged to be of investment grade quality by Angel Oak.
ABOUT ANGEL OAK CAPITAL ADVISORS, LLC
Angel Oak is an investment management firm focused on providing compelling fixed-income investment solutions to its clients. Backed by a value-driven approach, Angel Oak seeks to deliver attractive, risk-adjusted returns through a combination of stable current income and price appreciation. Its experienced investment team seeks the best opportunities in fixed income, with a specialization in mortgage-backed securities and other areas of structured credit.
On April 1, 2025, Angel Oak Companies, LP, the parent of Angel Oak Asset Management Holdings, LLC, itself the parent company of Angel Oak, announced that it signed a definitive agreement pursuant to which Brookfield Asset Management Ltd. will acquire a majority interest in Angel Oak Companies, LP and its subsidiaries, including Angel Oak (the 'Transaction'). The closing of the Transaction is expected to be completed by September 30, 2025. The Transaction is not expected to result in any material change in the day-to-day management of the Fund. However, the closing of the Transaction is subject to certain conditions, and there can be no assurance that the Transaction will be completed as planned, or that the necessary conditions will be satisfied. If successful, the closing of the Transaction would be deemed to be a change of 'control' of Angel Oak Companies, LP and its subsidiaries (collectively, the 'Angel Oak Companies'), including Angel Oak, under the Investment Company Act of 1940, and deemed 'assignment' of the Fund's investment advisory agreement (the 'Existing Advisory Agreement'), which would result in the automatic termination of the Existing Advisory Agreement. However, following the closing of the Transaction, the existing management team of the Angel Oak Companies will continue to independently manage the day-to-day business of the Angel Oak Companies and Angel Oak, and will control the boards of directors of the Angel Oak Companies.
Information regarding the Fund and Angel Oak can be found at www.angeloakcapital.com.
Past performance is neither indicative nor a guarantee of future results. Investors should read the prospectus supplement and accompanying prospectus and consider the investment objective and policies, risk considerations, charges and ongoing expenses of an investment carefully before investing. For more information, please contact your investment representative or EQ Fund Solutions LLC, the Fund's proxy solicitor, at 866-751-6314.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Deutsche Bank Resumed a Hold Rating on Endava plc (DAVA)
Deutsche Bank Resumed a Hold Rating on Endava plc (DAVA)

Yahoo

time12 minutes ago

  • Yahoo

Deutsche Bank Resumed a Hold Rating on Endava plc (DAVA)

Endava plc (NYSE:DAVA) is one of the . On July 16, Deutsche Bank resumed coverage on Endava plc (NYSE:DAVA) with a Hold rating and a $14 price target. The firm noted in a research report that the cautious rating reflects broader industry challenges, highlighting that the payments, processors, and IT services sectors have underperformed against the S&P 500 this year. This underperformance was driven by overly optimistic investor expectations around the November election that did not materialize. The analyst highlighted that trade uncertainties and concerns about consumer spending have made the outlook for the group very uncertain, which is the most uncertain in the last five years. Under the current market scenario, Deutsche Bank favors companies with consistent sales growth, margin expansion, and strong free cash flow generation. Endava plc (NYSE:DAVA) is a technology service provider specializing in digital transformation and engineering services. It helps clients design, develop, and deploy software products and platforms using agile and AI-driven approaches. While we acknowledge the potential of DAVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Barclays Cautious on West Pharma (WST) on Non-Core Weakness and Injectable Disruption Risks
Barclays Cautious on West Pharma (WST) on Non-Core Weakness and Injectable Disruption Risks

Yahoo

time12 minutes ago

  • Yahoo

Barclays Cautious on West Pharma (WST) on Non-Core Weakness and Injectable Disruption Risks

West Pharmaceutical Services Inc. (NYSE:WST) is one of the most oversold S&P 500 stocks so far in 2025. On June 24, Barclays analyst Luke Sergott began coverage on West Pharmaceutical Services (WST) with an Equal Weight rating and a price target of $245. In his view, while the company maintains a solid foothold in its core High-Value Products (HVP) segment, recent performance has been weighed down by challenges in its smaller, non-core areas. Specifically, Sergott points to issues in SmartDose and continuous glucose monitoring (CGM) manufacturing, which have had a disproportionate impact despite their relatively small size compared to the overall business. These segments have faced operational and growth hurdles, which have dragged on sentiment, even though they don't represent West's primary revenue drivers. A pharmacist holding a vial of a pharmaceutical product manufactured by West Pharmaceuticals. What stands out more, however, is the longer-term risk highlighted by the analyst: the potential disruption that could be posed by the development of oral GLP-1 treatments. As GLP-1 therapies shift toward oral formulations, the demand for some of West's injectable delivery systems could face pressure. Sergott flags this trend as a key factor to watch, given the strategic implications it may have for the company's core product lines over time. If we talk about future growth, the company views the HVP segment as a key driver, as it contributes approximately 60% of revenue and over 75% of gross profit. Between the various businesses in this segment, revenue is expected to rise by mid-single digits to high single digits over the long term. West Pharmaceutical Services Inc. (NYSE:WST) delivers value-added solutions throughout the drug development and delivery process. The company specializes in the development and manufacturing of injectable drug delivery systems, high-performance packaging components, and the development of innovative delivery technologies. It also offers contract laboratory and analytical services to support pharmaceutical and biotech partners worldwide. While we acknowledge the potential of WST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

RBC Maintains Neutral View on Conagra (CAG) as Q4 Miss Highlights Growth Pressures
RBC Maintains Neutral View on Conagra (CAG) as Q4 Miss Highlights Growth Pressures

Yahoo

time12 minutes ago

  • Yahoo

RBC Maintains Neutral View on Conagra (CAG) as Q4 Miss Highlights Growth Pressures

Conagra Brands Inc. (NYSE:CAG) is one of the most oversold S&P 500 stocks so far in 2025. The stock has declined around 30%–32% both YTD and over the past year, largely reflecting broader consumer weakness and persistent inflation, which continue to cloud the outlook for packaged food companies. Investor sentiment took a further hit following the company's Q4 FY 2025 results (fiscal year ended May), released on July 10. The numbers confirmed ongoing softness: net sales dropped 4.3% year-over-year, with organic sales falling 3.5%. While lower volumes were the primary driver of this decline, unfavorable price/mix also played a part. A busy supermarket with shelves full of packaged foods. Margins came under pressure, too. Adjusted operating margin contracted by 100 basis points to 13.8%, contributing to an 8% year-over-year decline in earnings per share, which came in at $0.56. Reacting to the results, RBC Capital's Nik Modi lowered Conagra's price target from $25 to $22, maintaining a Sector Perform rating. In his note to clients, Modi acknowledged the firm's Q4 miss and called attention to a cautious FY 2026 outlook, shaped by ongoing cost inflation and the impact of tariffs. Interestingly, Conagra appears to be leaning into the downturn by continuing to invest in its brands, improving supply chain flexibility, and supporting volume recovery, despite the near-term strain this puts on margins and sentiment. According to Modi, these investments are critical for rebuilding momentum, even if they come at a short-term cost. The market may remain cautious in the near term, but it may stabilize and recover depending on how effectively Conagra navigates these headwinds and how soon its investments begin to yield results. Conagra Brands Inc. (NYSE:CAG) is one of North America's leading branded food companies with a portfolio that includes brands such as Birds Eye, Duncan Hines, Healthy Choice, Marie Callender's, Reddi-wip, and Slim Jim. While we acknowledge the potential of CAG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store